FDA Won’t Raise the Bar for Drugs Referencing Novo Nordisk

Drug Industry Daily
A A
The FDA turned down a request from Novo Nordisk to deny ANDAs referencing its liraglutide-containing drugs without comparative studies.

To View This Article:

Login

Subscribe To Drug Industry Daily